Clinical Trial

Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

Study acronym: GUIDE2REPAIR
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study propose to generate a clinical trial based on precision medicine to evaluate the use of immunotherapy in patients with altered homologous recombination repair genes and without progression after prior targeted therapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-11-19; most recent amendment 2024-02-12.
Status change: Recruiting → Active, Not Recruiting 2024-02-12
Status change: Not Yet Recruiting → Recruiting 2021-05-21
Trial Details
NCT Number NCT04169841
Lead Sponsor Centre Georges Francois Leclerc
Collaborators: AstraZeneca
Conditions Immunotherapy
Enrollment 270 participants
Start Date 2020-02-10
Primary Completion 2027-08-10 (estimated)
Study Completion 2027-08-10 (estimated)
Updated on ClinicalTrials.gov 2024-02-13